You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 135 No. 7, July 2009 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Article
 This Article
 •Full text
 •PDF
 •CME Course for This Article
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Neurology
 •Neuro-otology
 •Endocrine Disease of Head & Neck
 •Genetics of Head & Neck Disease
 •Hearing Loss/ Deafness
 •Endocrine Diseases
 •Thyroid/ Parathyroid Diseases
 •Genetics
 •Genetic Disorders
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Evaluation of the Thyroid in Patients With Hearing Loss and Enlarged Vestibular Aqueducts

Anne C. Madeo, MS; Ani Manichaikul, PhD; James C. Reynolds, MD; Nicholas J. Sarlis, MD, PhD; Shannon P. Pryor, MD; Thomas H. Shawker, MD; Andrew J. Griffith, MD, PhD

Arch Otolaryngol Head Neck Surg. 2009;135(7):670-676.

Objective  To evaluate thyroid structure and function in patients with enlargement of the vestibular aqueduct (EVA) and sensorineural hearing loss.

Design  Prospective cohort survey.

Setting  National Institutes of Health Clinical Center, a federal biomedical research facility.

Patients  The study population comprised 80 individuals, aged 1.5 to 59 years, ascertained on the basis of EVA and sensorineural hearing loss.

Main Outcome Measures  Associations among the number of mutant alleles of SLC26A4; volume and texture of the thyroid; percentage of iodine 123 (123I) discharged at 120 minutes after administration of perchlorate in the perchlorate discharge test; and peripheral venous blood levels of thyrotropin, thyroxine, free thyroxine, triiodothyronine, thyroglobulin, antithyroid peroxidase and antithyroglobulin antibodies, and thyroid-binding globulin.

Results  Thyroid volume is primarily genotype dependent in pediatric patients but age dependent in older patients. Individuals with 2 mutant SLC26A4 alleles discharged a significantly (P ≤ .001) greater percentage of 123I compared with those with no mutant alleles or 1 mutant allele. Thyroid function, as measured by serologic testing, is not associated with the number of mutant alleles.

Conclusions  Ultrasonography with measurement of gland volume is recommended for initial assessment and follow-up surveillance of the thyroid in patients with EVA. Perchlorate discharge testing is recommended for the diagnostic evaluation of patients with EVA along with goiter, nondiagnostic SLC26A4 genotypes (zero or 1 mutant allele), or both.


Author Affiliations: Social and Behavioral Research Branch, National Human Genome Research Institute (Ms Madeo), Radiology and Imaging Sciences (Drs Reynolds and Shawker), Warren G. Magnuson Clinical Center, Clinical Endocrinology Branch, National Institute of Diabetes and Digestive and Kidney Diseases (Dr Sarlis), and Otolaryngology Branch, National Institute on Deafness and Other Communication Disorders (Drs Pryor and Griffith), National Institutes of Health, Bethesda, Maryland; and Department of Biomedical Engineering, University of Virginia, Charlottesville (Dr Manichaikul).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2009 American Medical Association. All Rights Reserved.